中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
25期
149-150
,共2页
沙丁胺醇%普米克令舒%小儿哮喘%急性发作
沙丁胺醇%普米剋令舒%小兒哮喘%急性髮作
사정알순%보미극령서%소인효천%급성발작
Albuterol%Pulmicort%Pediatric asthma%Acute attack
目的:观察并分析沙丁胺醇以及普米克令舒治疗小儿哮喘急性发作的效果以及应用价值。方法将2012年7月-2014年8月在该院接受治疗的100例哮喘急性发作的患儿作为此次研究的对象,按照随机分配的方法将患儿分为实验组(n=50)和对照组(n=50),给予对照组患儿常规治疗,在对照组的基础上,再给予实验组患儿沙丁胺醇以及普米克令舒进行治疗,观察两组患儿的临床治疗效果以及临床症状消失时间。结果实验组患儿的治疗总有效率明显高于对照组患儿(P<0.05),实验组患儿气促、咳嗽、憋喘以及啰音消退时间明显少于对照组患儿(P<0.05)。结论应用沙丁胺醇以及普米克令舒治疗小儿哮喘急性发作,其疗效确切,值得大力推广应用。
目的:觀察併分析沙丁胺醇以及普米剋令舒治療小兒哮喘急性髮作的效果以及應用價值。方法將2012年7月-2014年8月在該院接受治療的100例哮喘急性髮作的患兒作為此次研究的對象,按照隨機分配的方法將患兒分為實驗組(n=50)和對照組(n=50),給予對照組患兒常規治療,在對照組的基礎上,再給予實驗組患兒沙丁胺醇以及普米剋令舒進行治療,觀察兩組患兒的臨床治療效果以及臨床癥狀消失時間。結果實驗組患兒的治療總有效率明顯高于對照組患兒(P<0.05),實驗組患兒氣促、咳嗽、憋喘以及啰音消退時間明顯少于對照組患兒(P<0.05)。結論應用沙丁胺醇以及普米剋令舒治療小兒哮喘急性髮作,其療效確切,值得大力推廣應用。
목적:관찰병분석사정알순이급보미극령서치료소인효천급성발작적효과이급응용개치。방법장2012년7월-2014년8월재해원접수치료적100례효천급성발작적환인작위차차연구적대상,안조수궤분배적방법장환인분위실험조(n=50)화대조조(n=50),급여대조조환인상규치료,재대조조적기출상,재급여실험조환인사정알순이급보미극령서진행치료,관찰량조환인적림상치료효과이급림상증상소실시간。결과실험조환인적치료총유효솔명현고우대조조환인(P<0.05),실험조환인기촉、해수、별천이급라음소퇴시간명현소우대조조환인(P<0.05)。결론응용사정알순이급보미극령서치료소인효천급성발작,기료효학절,치득대력추엄응용。
Objective Observe and analyze the effect of albuterol and Pulmicort treatment of pediatric asthma exacerbations and Value. Methods The children from July 2013 to August 2014 in our hospital treated 100 cases of acute asthma as the object of this research, according to the random assignment of patients were divided into experimental group (n=50) and control group (n=50), administered to the control group of children with conventional treatment, on the basis of the control group, the experimental group of children and then give albuterol and Pulmicort treatment, clinical treatment and the clinical symptoms of the two groups of children disappearing time. Results Treatment of patients in the experimental group was significantly higher in patients with to-tal efficiency (P<0.05), the experimental group were shortness of breath, cough, dyspnea and crackles subside hold time was less than the control group patients (P<0.05). Conclusion Application of albuterol and Pulmicort treatment of pediatric asthma exacer-bations, its efficacy, worth promoting applications.